Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Indian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...

Indian equities are nearing a crucial turning point, with market veteran Gautam Shah suggesting a shift in focus beyond benchmark indices. ...

Indian equities surged nearly 1% as bulls charged through Dalal Street, driven by an Iran-US peace framework and sliding oil prices. The Se...

Easing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...

Markets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...

Amidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...

Global challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...

India is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Helios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...

Uzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...